JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation is allowed to use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website for educational purpose only. Bodily introduction of any kind into humans and animals is strictly forbidden by law. This product should only be handled by licenced qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused as a drug, food and cosmetic.
FREE Shipping for orders over $200
Exemestane is a steroid aromatase inhibitor and structurally related to the natural substrate androstenedione. Aromatase is referred to in biochemistry research as the enzyme responsible for converting androgenic precursors into estrogenic compounds in steroidogenesis pathways. Modulating the activity of aromatase is therefore considered as a molecular approach for controlling estrogen production in estrogen-sensitive signaling systems. It is reported that exemestane binds to the active centre of an enzyme where it irreversibly inactivates the enzyme, a phenomenon known as mechanism-based (or irreversible) inhibition.
Available research data demonstrate that Exemestane is selective to aromatase without androgenic effect related interaction with the adrenal steroidogenic system and does not have estrogenic or progestational activity. Its influence on upstream gonadotropin-related signaling is evaluated at the biochemical and regulatory pathway level rather than as a functional outcome. At Element CRP, liquid Exemestane is supplied exclusively for educational and laboratory research purposes. The compound is not intended for human or animal use, ingestion, or application in food, drug, or cosmetic products.
From Pubchem
IUPAC Name:(8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dioneSynonym: 107868-30-4, AromasinMolecular Formula: C20H24O2Molecular Weight: 296.4 g/molCAS Number: 107868-30-4PubChem CID: 60198
Molecular and biochemical research studies are being conducted on exemestane as an irreversible inactivator of aromatase, the enzyme complex responsible for producing estrogen. Formation of estrogen occurs via enzymatic conversion of androgenic precursors, the regulation of which has been explored to control estrogen-dependent transcriptional signaling. Exemestane is distinguished by a covalent bonding to the active site of aromatase, what leads to irreversible inactivation of enzyme and down regulation of catalytic activity in estrogen biosynthetic pathways.
Studies have concentrated on the molecular downstream effects of aromatase inactivation, involving changes in estrogen receptor–mediated gene expression, intra-cellular signaling equilibrium and feedback-regulatory mechanisms within the steroidogenic pathways.
Exemestane is also part of studies aimed at sequential modulation of estrogen-related pathways. Comparative studies explore features of reversible vs irreversible aromatase inhibition, focusing on enzyme kinetics, binding duration and signaling blockade. These investigations evaluate the depth of change in aromatase inhibition tactics and consider how this impact transcriptional control, receptor signalling adjustment, and pathway compensation.
Research attention is directed toward understanding signaling transitions following shifts in estrogen synthesis modulation, including receptor sensitivity, pathway redundancy, and molecular adaptation within hormone-responsive systems.
Exemestane is also examined in research contexts involving estrogen regulation mechanisms independent of ovarian steroidogenesis. These studies are centered on peripheral aromatization and local estrogen formation in tissue-specific microenvironment. Molecular analyses assess the effects of irreversible aromatase inhibition on local estrogen signaling, and receptor-mediated gene transcription in the face of suppressed gonadal contribution.
Despite being in the era of functional and clinical interpretation, there still is a focus on coordination of intracellular signals, enzyme- receptor interactions and regulation of feedback pathways.
Estrogen receptor signaling interfaces with intracellular kinase cascades, such as the PI3K/AKT/mTOR axis, in the control of cellular growth, metabolism and survival. The indirect impact of exemestane on these signalling systems by decreasing oestrogen formation and receptor mediated transcription is reviewed and considered.
Research pipelines focus on the discovery of combinatorial modulation on pathway alteration to provide insights into signaling convergence, resistance-related adaptations and compensatory kinase activation at a molecular level without any consideration being given to therapy purpose.
Exemestane is a steroidal irreversible aromatase inhibitor and use in lab studies, to research estrogen synthesis, inactivation kinetics of the enzyme and hormone-regulated signaling pathways. Current investigations are looking at its use as a molecular probe to study steroid metabolism, receptor-dependent transcriptional regulation and intracellular pathway crosstalk.
At Element CRP, Exemestane (Aromasin) is supplied exclusively for research and educational purposes. The compound is intended strictly for laboratory investigation and is not approved for human or animal use, ingestion, or application in food, drug, or cosmetic products.
Exemestane is a steroidal small-molecule irreversible aromatase inhibitor structurally derived from androstenedione. Unlike non-steroidal aromatase inhibitors, it forms a covalent bond with the CYP19A1 active site, delivering distinct mechanistic pharmacology suitable for comparative in vitro enzyme research.
Cell-based research with Exemestane examines irreversible suicide inhibition of CYP19A1 in granulosa cell line models and aromatase-expressing cell preparations. In vitro studies map enzyme inactivation kinetics, comparative pharmacology against reversible inhibitors (Letrozole, Anastrozole), and downstream effects on estrogen biosynthesis pathway activity.
Element CRP supplies this product at 25mg/mL × 30mL. USA-manufactured via chemical synthesis and verified at 99%+ purity by HPLC and Mass Spectrometry. Pre-mixed liquid solution in 30mL or 60mL bottle with dropper; ready for laboratory use. Store at 15-25°C, away from direct light.
WARNING: For research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any disease. For use by qualified research professionals only.
Forgot password?
Country: United States (US-only registration)
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
Element CRP is a chemical supplier. Element CRP is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. Element CRP is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.
